The patient population RxUtility is built for is the person standing at a pharmacy counter who hears the price and walks out without the bottle. According to a December 2025 report the company published, Americans abandon roughly 98 million prescriptions annually because of cost [Business Wire, Dec 2025].
Nashville-based RxUtility, founded by health IT veteran Miriam Paramore, is trying to make that walk-away moment less common by giving every actor in the prescription chain the same real-time view of what a drug will actually cost the patient. The company sells an API that aggregates manufacturer copay coupons and surfaces real-time cash discount card pricing at every pharmacy [RxUtility].
The standard of care today
Medication affordability is currently held together by a patchwork. A prescriber writes a script with little visibility into what the patient will pay at their specific pharmacy. The pharmacist runs the claim, quotes a price, and, if the patient balks, may suggest a discount card, hunt for a manufacturer coupon, or call the prescriber to switch to a cheaper alternative. The result is the abandonment number RxUtility cites, and a clinical reality where adherence drops sharply the moment out-of-pocket cost crosses a patient's threshold.
The bet
RxUtility's wedge is the data layer underneath that mess. The company aggregates manufacturer copay coupons and real-time cash discount card pricing, delivered via API so partners can embed savings directly into their own workflows [RxUtility]. RxUtility is not asking patients to download an app; it is asking the systems patients already touch,e-prescribing tools, pharmacy management systems, employer benefits portals, and digital health apps,to surface a better price automatically.
In February 2026, the company announced a partnership with Buzz Health to boost medication price transparency for consumers, connecting providers, pharmacists, employers, payers, and digital health partners with real-time access to copay assistance and pricing [Business Wire, Feb 2026].
Opportunity
The tailwinds are aligned. The Inflation Reduction Act's drug pricing provisions, CMS pressure on PBM transparency, and employer frustration with specialty drug spend have pushed price transparency into a procurement requirement. Direct primary care practices are actively looking for cash-pay tooling. Paramore has been spotted at the Hint Summit, the main DPC industry gathering, describing how RxUtility can help that community [LinkedIn].
| Metric | Value |
|---|---|
| Abandoned US prescriptions per year (millions) | 98 |
The team and traction
Paramore is the CEO and founder. She was appointed President of OptimizeRx in 2017, where she focused on medication affordability, compliance, and real-time coupon distribution at the point of care [GlobeNewswire, Jul 2017]. Before that she held senior roles including COO and CTO of Lucro, EVP at PDX, and EVP of Strategy and Product at Emdeon [Fierce Healthcare].
The honest counterfactual
Bears will say that the real-time prescription pricing category already has well-funded incumbents. GoodRx owns consumer mindshare on cash discount cards. OptimizeRx sits inside EHR workflows for branded copay messaging. Surescripts and the major EHR vendors have invested in real-time benefit check infrastructure. Any new API entrant must convince integration partners that a single aggregated source is worth swapping in for tooling they already license. Bulls will answer that none of those incumbents combine cash discount pricing, manufacturer coupons, and pharmacy-level real-time data in one developer-facing API, and that the buyer set RxUtility is courting is precisely the segment underserved by tools designed for traditional payer workflows.
What to watch
The next 12 months will turn on three things. First, additional named integration partners in the mold of Buzz Health would signal the API is being adopted as infrastructure. Second, watch for any disclosed institutional funding round. Third, watch whether RxUtility publishes outcomes data showing measurable lift in fill rates for a defined patient cohort. If that evidence arrives, the conversation about RxUtility shifts from interesting plumbing to clinical tool.